Journal
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 48, Issue 6, Pages 2704-2712Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2016.3470
Keywords
multiple myeloma; mangiferin; NF-kappa B; anticancer drug; p53; Noxa; X-linked inhibitor of apoptosis protein; survivin; Bcl-xL
Categories
Funding
- Japan Society for the Promotion of Science (JSPS)
- Ministry of Education, Culture, Sports, Science, and Technology (MEXT)
- Grants-in-Aid for Scientific Research [16K08313, 15K00898, 26350597] Funding Source: KAKEN
Ask authors/readers for more resources
Multiple myeloma (MM) is still an incurable hematological malignancy with a 5-year survival rate of 35%, despite the use of various treatment options. The nuclear factor kappa B (NF-kappa B) pathway plays a crucial role in the pathogenesis of MM. Thus, inhibition of the NF-kappa B pathway is a potential target for the treatment of MM. In a previous study, we showed that mangiferin suppressed the nuclear translocation of NF-kappa B. However, the treatment of MM involves a combination of two or three drugs. In this study, we examined the effect of the combination of mangiferin and conventional anticancer drugs in an MM cell line. We showed that the combination of mangiferin and an anticancer drug decreased the viability of MM cell lines in comparison with each drug used separately. The decrease in the combination of mangiferin and an anticancer drug induced cell viability was attributed to increase the expression of p53 and Noxa and decreases the expression of XIAP, survivin, and Bcl-xL proteins via inhibition of NF-kappa B pathway. In addition, the combination treatment caused the induction of apoptosis, activation of caspase-3 and the accumulation of the cells in the sub-G1 phase of the cell cycle. Our findings suggest that the combination of mangiferin and an anticancer drug could be used as a new regime for the treatment of MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available